Mesenchymal stromal cells for acute respiratory distress syndrome (ARDS), sepsis, and COVID-19 infection: optimizing the therapeutic potential. (2021)
Attributed to:
A GMP cell therapy facility to test cell based therapies
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1080/17476348.2021.1848555
PubMed Identifier: 33172313
Publication URI: http://europepmc.org/abstract/MED/33172313
Type: Journal Article/Review
Volume: 15
Parent Publication: Expert review of respiratory medicine
Issue: 3
ISSN: 1747-6348